| May 26 | May 25 | May 24 | May 23 | May 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ -5.92M | $ 0.00 | $ 0.00 | $ 266.00K |
| Gross Profit | $ -17.00K | $ -18.00K | $ -29.00K | $ -175.00K | $ 213.00K |
| Operating Income | $ -21.81M | $ 11.32M | $ -18.06M | $ -40.58M | $ -145.40M |
| EBITDA | $ -21.79M | $ 8.62M | $ -18.03M | $ -40.40M | $ -194.97M |
| Net Income | $ -42.70M | $ 3.75M | $ -49.84M | $ -79.82M | $ -210.82M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 11.85M | $ 11.90M | $ 3.11M | $ 2.54M | $ 4.23M |
| Total Assets | $ 13.97M | $ 18.05M | $ 11.14M | $ 11.29M | $ 29.18M |
| Total Debt | $ 38.34M | $ 27.34M | $ 30.08M | $ 35.41M | $ 36.80M |
| Net Debt | $ 26.49M | $ 15.44M | $ 26.97M | $ 32.87M | $ 32.57M |
| Total Liabilities | $ 123.69M | $ 114.09M | $ 127.89M | $ 120.79M | $ 123.58M |
| Stockholders' Equity | $ -109.72M | $ -96.04M | $ -116.76M | $ -109.50M | $ -94.40M |
| Cash Flow | |||||
| Free Cash Flow | $ -17.25M | $ -8.77M | $ -10.98M | $ -25.11M | $ -77.72M |
| Operating Cash Flow | $ -17.25M | $ -8.77M | $ -10.98M | $ -25.11M | $ -77.72M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 17.20M | $ 10.85M | $ 11.75M | $ 29.93M | $ 48.01M |
CytoDyn Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.